Lipoproteins and mitogen-activated protein kinase signaling: A role in atherogenesis?

Current Opinion in Lipidology

Volumn 17, Issue 2, 2006, Pages 110-121

  Dobreva, Iveta ^a   Waeber, Gérard ^a,b   Widmann, Christian ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Lipoproteins; Mitogen activated protein kinase pathways; Proliferation; Signaling

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1,2 BIS(2 AMINO 5' METHYLPHENOXY)ETHANE N,N,N',N' TETRAACETIC ACID TETRAACETOXYMETHYL ESTER; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLCYSTEINE; CALCIUM CHELATING AGENT; CALPHOSTIN C; DIPHENYLIODONIUM SALT; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; G PROTEIN COUPLED RECEPTOR; GENISTEIN; INDOMETACIN DERIVATIVE; INDOMETACIN HEPTYL ESTER; LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PERTUSSIS TOXIN; PROTEIN TYROSINE KINASE; RAPAMYCIN; SCAVENGER RECEPTOR BI; SPHINGOSINE 1 PHOSPHATE; TIRON; UNCLASSIFIED DRUG; WORTMANNIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL; CELL HYPERPLASIA; CELL MEMBRANE TRANSPORT; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CHOLESTEROL TRANSPORT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 33645523271     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000217891.92993.53     Document Type: Review

References (76)

1. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11:93-102.
2. Heinecke JW. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol 1997; 8:268-274.
3. Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 1996; 16:416-424.
4. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15:2073-2084.
5. Widmann C, Gibson S, Jarpe MB, Johnson GL. MAPK pathways: conservation of athree-kinase module from yeast to man. Physiol Rev 1999; 79:143-180.
6. Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr Opin Chem Biol 2005; 9:325-331.
7. Pacheco YM, Abia R, Olivera A, et al. Sphingosine 1-phosphate signal survival and mitogenesis are mediated by lipid-stereospecific binding of triacylglycerol-rich lipoproteins. Cell Mol Life Sci 2003; 60:2757-2766.
8. Domoto K, Taniguchi T, Takaishi H, et al. Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells. Atherosclerosis 2003; 171:193-200.
9. Nofer JR, Junker R, Pulawski E, et al. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost 2001; 85:730-735.
10. Zhao D, Letterman J, Schreiber BM. β-Migrating very low density lipoprotein (βVLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on βVLDL plus EGF-induced cell proliferation. J Biol Chem 2001; 276:30579-30588.
11. Gouni-Berthold I, Berthold HK, Seul C, et al. Effects of authentic and VLDL hydrolysis-derived fatty acids on vascular smooth muscle cell growth. Br J Pharmacol 2001; 132:1725-1734.
12. Lipskaia L, Pourci ML, Delomenie C, et al. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res 2003; 92:1115-1122.
13. Yang CM, Chien CS, Hsiao LD, et al. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/ Raf/MEK/MAPK pathway. Br J Pharmacol 2001; 132:1531-1541.
14. Sachinidis A, Seewald S, Epping P, et al. The growth-promoting effect of low-density lipoprotein may be mediated by a pertussis toxin-sensitive mitogen-activated protein kinase pathway. Mol Pharmacol 1997; 52:389-397.
15. Hu Y, Dietrich H, Metzler B, et al. Hyperexpression and activation of extracellular signal-regulated kinases (ERK1/2) in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 2000; 20:18-26.
16. Locher R, Brandes RP, Vetter W, Barton M. Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension 2002; 39:645-650.
17. Dobreva I, Zschörnig O, James RW, et al. Cholesterol is the major component of native lipoproteins activating the p38 MAPKs. Biol Chem 2005; 368:909-918.
18. Jing Q, Xin SM, Cheng ZJ, et al. Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: mediation via pertussis toxin-sensitive G proteins and association with oxidized LDL-induced cytotoxicity. Circ Res 1999; 84:831-839.
19. Rius J, Martinez-Gonzalez J, Crespo J, Badimon L. Involvement of neuron-derived orphan receptor-1 (NOR-1) in LDL-induced mitogenic stimulus in vascular smooth muscle cells: role of CREB. Arterioscler Thromb Vasc Biol 2004; 24:697-702. This study describes the molecular mechanism employed by LDLs to induce vascular smooth muscle cell proliferation. It shows that pertussis toxin-sensitive GPCR, Ca2+ mobilization, PKC, the ERK and the p38 MAPK pathways are all involved in the upregulation of neuron-derived orphan receptor 1, a transcription factor mediating vascular smooth muscle cell proliferation in response to LDL.
20. Kusuhara M, Chait A, Cader A, Berk BC. Oxidized LDL stimulates mitogen-activated protein kinases in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 1997; 17:141-148.
21. Metzler B, Li C, Hu Y, et al. LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:1862-1871.
22. Auge N, Escargueil-Blanc I, Lajoie-Mazenc I, et al. Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein. J Biol Chem 1998; 273:12893-12900.
23. Napoli C, Quehenberger O, De Nigris F, et al. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J 2000; 14:1996-2007.
24. Metzler B, Hu Y, Dietrich H, Xu Q. Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am J Pathol 2000; 156:1875-1886.
25. Vinals M, Martinez-Gonzalez J, Badimon L. Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol 1999; 19:2405-2411.
26. Martinez-Gonzalez J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis 2004; 174:305-313.
27. Norata GD, Pirillo A, Callegari E, et al. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 2003; 59:169-180.
28. Maier JA, Barenghi L, Bradamante S, Pagani F. Induction of human endothelial cell growth by mildly oxidized low density lipoprotein. Atherosclerosis 1996; 123:115-121.
29. 2 synthesis. Int J Mol Med 2004; 14:353-359.
30. Zhu Y, Liao H, Wang N, et al. LDL-activated p38 in endothelial cells is mediated by Ras. Arterioscler Thromb Vasc Biol 2001; 21:1159-1164.
31. Zhu Y, Liao H-L, Wang N, et al. Low-density lipoprotein activates Jun N-terminal kinase (JNK) in human endothelial cells. Biochim Biophys Acta 1999; 1436:557-564.
32. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003; 23:1283-1288.
33. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001; 7:853-857. Demonstration using SR-BI knock-out mice of the critical role of SR-BI in HDL-stimulated eNOS activity in endothelial cells and for HDL-induced NO-dependent aortic relaxation.
34. Nihei S, Yamashita K, Tasaki H, et al. Oxidized low-density lipoprotein-induced apoptosis is attenuated by insulin-activated phosphatidylinositol 3-kinase/Akt through p38 mitogen-activated protein kinase. Clin Exp Pharmacol Physiol 2005; 32:224-229.
35. Zhang X, Hu K, Li CY. Protection against oxidized low-density lipoprotein-induced vascular endothelial cell death by integrin-linked kinase. Circulation 2001; 104:2762-2766.
36. Miura S, Fujino M, Matsuo Y, et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23:802-808. Demonstration that HDLs promote angiogenesis via stimulation of a PTX-sensitive GPCR followed by the activation of the ERK MAPK pathway.
37. Kimura T, Sato K, Kuwabara A, et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276:31780-31785.
38. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004; 24:871-877.
39. Norata GD, Banfi C, Pirillo A, et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br J Haematol 2004; 127:97-104.
40. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278:9142-9149.
41. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003; 13:226-231.
42. Nofer JR, van der GM, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581.
43. Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480-34485.
44. Dobreva I, Waeber G, Mooser V, et al. LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway. J Lipid Res 2003; 44:2382-2390.
45. Dobreva I, Waeber G, James RW, Widmann C. IL-8 secretion by fibroblasts induced by low-density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure. J Biol Chem 2006; 281:199-205.
46. Han J, Hajjar DP, Zhou X, et al. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem 2002; 277:23582-23586.
47. Deeg MA, Bowen RF, Oram JF, Bierman EL. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Arterioscler Thromb Vasc Biol 1997; 17:1667-1674.
48. Grewal T, de DI, Kirchhoff MF, et al. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem 2003; 278:16478-16481. This study presents a compelling evidence that SR-BI is involved in the activation of the Ras/Raf/MEK1/ERK MAPK pathway in response to HDL.
49. Jing Q, Xin SM, Zhang WB, et al. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res 2000; 87:52-59.
50. Hundal RS, Salh BS, Schrader JW, et al. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res 2001; 42:1483-1491.
51. Deigner HP, Claus R. Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett 1996; 385:149-153.
52. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351:95-105.
53. Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50:77-82.
54. Toullec D, Pianettis P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266:15771-15781.
55. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994; 269:5241-5248.
56. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144:251-258.
57. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
58. Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993; 73:585-596.
59. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999; 40:187-201.
60. Cherradi N, Bideau M, Arnaudeau S, et al. Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I. Endocrinology 2001; 142:4540-4549.
61. Graf GA, Connell PM, Van Der Westhuyzen DR, Smart EJ. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J Biol Chem 1999; 274:12043-12048.
62. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275:17221-17224.
63. Incardona JP, Eaton S. Cholesterol in signal transduction. Curr Opin Cell Biol 2000; 12:193-203. A must-read review for those interested in the role played by cholesterol in signal transduction.
64. Sheets ED, Holowka D, Baird B. Critical role for cholesterol in Lyn-mediated tyrosine phosphorylation of FcepsilonRI and their association with detergent-resistant membranes. J Cell Biol 1999; 145:877-887.
65. Xavier R, Brennan T, Li Q, et al. Membrane compartmentation is required for efficient T cell activation. Immunity 1998; 8:723-732.
66. Pike LJ, Miller JM. Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J Biol Chem 1998; 273:22298-22304.
67. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4:397-407. A good overview on the multiple cellular effects of S1P and its central role in the regulation of cell death and survival. The role of S1P-mediated signalling is discussed in detail as well as its importance in cell growth, migration and angiogenesis.
68. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379:557-560.
69. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004; 116:191-203.
70. Downward J. Control of ras activation. Cancer Surv 1996; 27:87-100.
71. Roberts KA, Woo MM, Rutledge JC. Nitric oxide mediates LDL uptake in the artery wall in response to high concentrations of 17 beta-estradiol. Arterioscler Thromb Vasc Biol 1997; 17:2123-2131.
72. Stepp DW, Ou J, Ackerman AW, et al. Native LDL and minimally oxidized LDL differentially regulate superoxide anion in vascular endothelium in situ. Am J Physiol Heart Circ Physiol 2002; 283:H750-H759.
73. Moulton KS. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001; 3:225-233.
74. Ohashi N, Matsumori A, Furukawa Y, et al. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2000; 20:2521-2526. Characterization of the in vivo role of the p38 MAPK pathway in the vascular response to injury. Of particular note is the observation that inhibition of p38 MAPKs abrogates the induction of the proinflammatory cytokine IL-1b and neointima formation in injured arteries. This suggests that the p38 MAPK pathway plays a critical role in the progression of atherosclerosis.
75. Kritchevsky D. Atherosclerosis and nutrition. Nutr Int 1986; 2:290-297.
76. Hersberger M, von Eckardstein A. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Drugs 2003; 63:1907-1945. This review article provides thorough information on the structure and function of the HDL particles as well as the biochemical mechanisms of their action. It also gives a critical insight into the association between HDL and atherosclerosis from clinical studies.